NEWTON, Mass.--(BUSINESS WIRE)--Lumicell, Inc., a privately held company focused on developing innovative fluorescence-guided imaging technologies for cancerous tissue detection during surgery, is ...
NEWTON, Mass.--(BUSINESS WIRE)--Lumicell, Inc., a privately held company focused on developing innovative fluorescence-guided imaging technologies for cancerous tissue detection during surgery, today ...
The FDA approved pegulicianine (LumiSight) as an optical imaging agent for detecting residual cancer after breast-conserving surgery (BCS). The approval stipulates use of pegulicianine with the ...
NEWTON, Mass., Dec. 18, 2025 /PRNewswire/ -- Lumicell, Inc., a leader in developing innovative fluorescence-guided imaging technologies for cancer detection, today announced a new collaboration with ...
One in eight U.S. women will be diagnosed with breast cancer during their lifetime, and many of these patients will undergo a lumpectomy, a surgical treatment to remove the tumor while preserving as ...
Many women who are diagnosed with breast cancer face the difficult decision of whether to have a lumpectomy with radiation or a mastectomy with reconstruction. With the availability of study results ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results